SCHOLAR ROCK HOLDING CORP (SRRK) competitors & alternatives
Health Care · NASDAQ
SCHOLAR ROCK HOLDING CORP (SRRK)'s top competitors and alternatives — its most similar public companies — include Biogen (BIIB), NOVARTIS AG (NVS), CYTOKINETICS INC (CYTK), VIRIDIAN THERAPEUTICS ORS INC (VRDN), MIRUM PHARMACEUTICALS INC (MIRM), PROTHENA PLC (PRTA), Ultragenyx (RARE), KINIKSA PHARMACEUTICALS INTERNATIO (KNSA), SPYRE THERAPEUTICS INC (SYRE), DYNE THERAPEUTICS INC (DYN), SHATTUCK LABS INC (STTK) and TG THERAPEUTICS INC (TGTX). These are SCHOLAR ROCK HOLDING CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SRRK competitors & alternatives
-
BiogenBIIBHealth Care
Biogen is a global biotechnology company developing and commercializing therapies across neurology, immunology, and rare genetic disease.
$197.74 (as of 2026-07-22) · market cap $29.8B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
CYTOKINETICS INCCYTKHealth Care
A biopharmaceutical company pioneering small-molecule cardiac myosin inhibitors and muscle-directed therapies to improve heart and neuromuscular function in…
$82.19 (as of 2026-07-22) · market cap $10.4B
-
VIRIDIAN THERAPEUTICS ORS INCVRDNHealth Care
Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and…
$19.17 (as of 2026-07-22) · market cap $2.1B
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
PROTHENA PLCPRTAHealth Care
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through…
$8.44 (as of 2026-07-22) · market cap $458M
-
UltragenyxRAREHealth Care
Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
$27.65 (as of 2026-07-22) · market cap $2.8B
-
KINIKSA PHARMACEUTICALS INTERNATIOKNSAHealth Care
Kiniksa is a biopharmaceutical company commercializing ARCALYST (IL-1 cytokine trap) for recurrent pericarditis and rare inflammatory diseases, with a pipeline…
$62.44 (as of 2026-07-22) · market cap $4.8B
-
SPYRE THERAPEUTICS INCSYREHealth Care
Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases…
$99.17 (as of 2026-07-22) · market cap $8.6B
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
SHATTUCK LABS INCSTTKHealth Care
Shattuck Labs is a clinical-stage biotech developing novel protein therapeutics to treat inflammatory and immune-mediated diseases by targeting the DR3/TL1A…
$7.02 (as of 2026-07-22) · market cap $634M
-
TG THERAPEUTICS INCTGTXHealth Care
Commercial-stage biotech focused on anti-CD20 monoclonal antibody therapies for B-cell diseases, with FDA-approved BRIUMVI for relapsing multiple sclerosis and…
$52.68 (as of 2026-07-22) · market cap $8.3B
Not quite? Describe exactly what you want →
Peers are SCHOLAR ROCK HOLDING CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: SCHOLAR ROCK HOLDING CORP (SRRK).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.